2006
DOI: 10.1097/01.mph.0000212991.64435.f0
|View full text |Cite
|
Sign up to set email alerts
|

Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome

Abstract: Rituximab seems efficacious and safe as adjunctive therapy for OMS. Selective targeting of CSF B lymphocytes represents a novel and valuable paradigm shift in the therapy for centrally mediated paraneoplastic disorders.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

4
68
0

Year Published

2009
2009
2014
2014

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 128 publications
(72 citation statements)
references
References 47 publications
4
68
0
Order By: Relevance
“…In both patients there was very significant B-cell expansion, similar to or higher than that described in cases of opsoclonusmyoclonus syndrome, a putative autoimmune disorder that can be treated with rituximab. 7 This finding supports the role of CSF humoral autoimmunity in both the acute and relapsing course of NMDAR encephalitis. Given the fact that many patients with NMDAR encephalitis exhibit intrathecal synthesis of NMDAR antibody, B-cell expansion and differentiation would be anticipated and expected.…”
Section: Discussionsupporting
confidence: 75%
See 2 more Smart Citations
“…In both patients there was very significant B-cell expansion, similar to or higher than that described in cases of opsoclonusmyoclonus syndrome, a putative autoimmune disorder that can be treated with rituximab. 7 This finding supports the role of CSF humoral autoimmunity in both the acute and relapsing course of NMDAR encephalitis. Given the fact that many patients with NMDAR encephalitis exhibit intrathecal synthesis of NMDAR antibody, B-cell expansion and differentiation would be anticipated and expected.…”
Section: Discussionsupporting
confidence: 75%
“…6,7 We present our findings of CSF B-cell expansion in a child with acute NMDAR encephalitis and in another child with relapsing NMDAR encephalitis. Both children had substantial expansion of B-cells in the CSF, a finding that supports the use of drugs such as rituximab that target CD20 + B-cells.…”
mentioning
confidence: 98%
See 1 more Smart Citation
“…Thus, our experimental results supported the immunological evidence that this patient's serum sample includes an antibody with affinity to NMDAR. Rituximab causes a decrease in B cells and prevents maturation of these cells into antibody-secreting cells (10); it also suppresses B cell function more selectively and continuously than first-line immunotherapy (13)(14)(15)(16)(17)(18)(19). In addition, this agent causes a form of immune system resetting due to the depletion of memory B cells (19,20).…”
Section: Discussionmentioning
confidence: 99%
“…Treatment possibility is less in children when compared to adults (Bataller et al, 2001). Rituximab therapy may be tried in suitable patients (Pranzatelli et al, 2006).…”
Section: Opsoclonus-myoclonusmentioning
confidence: 99%